Literature DB >> 8364915

Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis.

R Grobholz1, H J Hacker, B Thorens, P Bannasch.   

Abstract

Expression of two important glucose transporter proteins, GLUT 2 (which is the typical glucose transporter in hepatocytes of adult liver) and the erythroid/brain type glucose transporter GLUT 1 (representing the typical glucose transporter in fetal liver parenchyma), was studied immunocytochemically during hepatocarcinogenesis in rats at different time points between 7 and 65 wk after cessation of 7-wk administration of 12 mg/kg of body weight of N-nitrosomorpholine p.o. (stop model). Foci of altered hepatocytes excessively storing glycogen (GSF) and mixed cell foci (MCF) composed of both glycogenotic and glycogen-poor cells were present at all time points studied. Seven wk after withdrawal of the carcinogen, GSF were the predominant type of focus of altered hepatocytes. Morphometrical evaluation of the focal lesions revealed that the number and volume fraction of GSF increased steadily until Wk 65. MCF were rare at 7 wk, increased slightly in number and size until Wk 37, but showed a pronounced elevation in their number and volume fraction from Wk 37 to Wk 65. In both GSF and MCF, GLUT 2 was generally decreased or partially absent at all time points. Consequently, foci of decreased GLUT 2 expression showed a steady increase in number and volume fraction from Wk 7 to Wk 65. GLUT 1 was lacking in GSF but occurred in some MCF from Wk 50 onward. The liver type glucose transporter GLUT 2 was decreased in all adenomas and hepatocellular carcinomas (HCC). In three of seven adenomas and 10 of 12 carcinomas, expression of GLUT 1 was increased compared with normal liver parenchyma. In two cases of adenoid HCC, cells of ductular formations coexpressed GLUT 2 and GLUT 1. In contrast, normal bile ducts, bile duct proliferations, and cystic cholangiomas expressed only GLUT 1. Seven of 12 HCC contained many microvessels intensely stained for GLUT 1, a phenomenon never observed in normal liver. Whenever adenoid tumor formations occurred, GLUT 1-positive microvessels were located in the immediate vicinity of these formations. Only in one HCC were such microvessels found in the absence of adenoid formations. Our studies indicate that a reduction of GLUT 2 expression occurs already in early preneoplastic hepatic foci and is maintained throughout hepatocarcinogenesis, including benign and malignant neoplasms. Reexpression of GLUT 1, however, appears in a few MCF and in the majority of adenomas and carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364915

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Drugging cancer metabolism: Expectations vs. reality.

Authors:  David C Montrose; Lorenzo Galluzzi
Journal:  Int Rev Cell Mol Biol       Date:  2019-07-29       Impact factor: 6.813

Review 2.  Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone.

Authors:  P Bannasch; F Klimek; D Mayer
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

3.  Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.

Authors:  Mei Tian; Hong Zhang; Yoshiki Nakasone; Kenji Mogi; Keigo Endo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-10       Impact factor: 9.236

4.  Altered liver acini induced in diabetic rats by portal vein islet isografts resemble preneoplastic hepatic foci in their enzymic pattern.

Authors:  F Dombrowski; E Filsinger; P Bannasch; U Pfeifer
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

5.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

6.  Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma.

Authors:  Katjana Daskalow; David Pfander; Wilko Weichert; Nadine Rohwer; Armin Thelen; Peter Neuhaus; Sven Jonas; Bertram Wiedenmann; Christoph Benckert; Thorsten Cramer
Journal:  Histochem Cell Biol       Date:  2009-04-07       Impact factor: 4.304

7.  MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients.

Authors:  E R F Siqueira; C P M S Oliveira; M L Correa-Giannella; J T Stefano; A M Cavaleiro; M A H Z Fortes; M T C Muniz; F S Silva; L M M B Pereira; F J Carrilho
Journal:  Braz J Med Biol Res       Date:  2011-12-09       Impact factor: 2.590

8.  Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma.

Authors:  Shamir Cassim; Valérie-Ann Raymond; Benoit Lacoste; Pascal Lapierre; Marc Bilodeau
Journal:  Oncotarget       Date:  2018-06-01

Review 9.  Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.

Authors:  Serena De Matteis; Andrea Ragusa; Giorgia Marisi; Stefania De Domenico; Andrea Casadei Gardini; Massimiliano Bonafè; Anna Maria Giudetti
Journal:  Oxid Med Cell Longev       Date:  2018-11-04       Impact factor: 6.543

10.  SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma.

Authors:  Yun Hak Kim; Dae Cheon Jeong; Kyoungjune Pak; Myoung-Eun Han; Ji-Young Kim; Liu Liangwen; Hyun Jin Kim; Tae Woo Kim; Tae Hwa Kim; Dong Woo Hyun; Sae-Ock Oh
Journal:  Oncotarget       Date:  2017-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.